Chongqing Zhifei Biological Products (300122.SZ) Receives Approval for Clinical Trial Application of Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine

Stock News2025-12-17

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. ("Zhifei Longcom"), has received the acceptance notice (No. CXSL2501083) from the National Medical Products Administration (NMPA) for the clinical trial application of its Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine.

If no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with clinical trials according to the submitted protocol.

The vaccine adopts an attenuated live vaccine technology route, utilizing the Modified Vaccinia Ankara (MVA) strain for production. The MVA strain cannot effectively replicate in human cells, preventing systemic spread or secondary transmission, thereby ensuring high safety.

The acceptance of this clinical trial application marks a critical breakthrough in the company's emerging infectious disease vaccine portfolio, demonstrating its commitment to innovation and core technological advancement. This milestone not only strengthens the company's long-term growth prospects but also enhances China's independent innovation capabilities in major infectious disease prevention and control.

Successful development of this project will further diversify the company's vaccine pipeline, optimize its product portfolio, and reinforce its market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165688332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165688332","market":"nz","top_or_hot":-1,"title":"Chongqing Zhifei Biological Products (300122.SZ) Receives Approval for Clinical Trial Application of Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine","media":"Stock News","content":"<p>Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance notice (No. CXSL2501083) from the National Medical Products Administration (NMPA) for the clinical trial application of its Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine.</p>\n<p>If no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with clinical trials according to the submitted protocol.</p>\n<p>The vaccine adopts an attenuated live vaccine technology route, utilizing the Modified Vaccinia Ankara (MVA) strain for production. The MVA strain cannot effectively replicate in human cells, preventing systemic spread or secondary transmission, thereby ensuring high safety.</p>\n<p>The acceptance of this clinical trial application marks a critical breakthrough in the company's emerging infectious disease vaccine portfolio, demonstrating its commitment to innovation and core technological advancement. This milestone not only strengthens the company's long-term growth prospects but also enhances China's independent innovation capabilities in major infectious disease prevention and control.</p>\n<p>Successful development of this project will further diversify the company's vaccine pipeline, optimize its product portfolio, and reinforce its market competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Zhifei Biological Products (300122.SZ) Receives Approval for Clinical Trial Application of Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Zhifei Biological Products (300122.SZ) Receives Approval for Clinical Trial Application of Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-17 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance notice (No. CXSL2501083) from the National Medical Products Administration (NMPA) for the clinical trial application of its Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine.</p>\n<p>If no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with clinical trials according to the submitted protocol.</p>\n<p>The vaccine adopts an attenuated live vaccine technology route, utilizing the Modified Vaccinia Ankara (MVA) strain for production. The MVA strain cannot effectively replicate in human cells, preventing systemic spread or secondary transmission, thereby ensuring high safety.</p>\n<p>The acceptance of this clinical trial application marks a critical breakthrough in the company's emerging infectious disease vaccine portfolio, demonstrating its commitment to innovation and core technological advancement. This milestone not only strengthens the company's long-term growth prospects but also enhances China's independent innovation capabilities in major infectious disease prevention and control.</p>\n<p>Successful development of this project will further diversify the company's vaccine pipeline, optimize its product portfolio, and reinforce its market competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"","article_id":"1165688332","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165688332","pubTimestamp":1765961329,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300122":"智飞生物","BK0077":"质押式回购","BK0196":"行业龙头","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0046":"生物疫苗","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"重庆智飞生物制品（300122.SZ）改良安卡拉痘苗病毒（MVA）猴痘减毒活疫苗临床试验申请获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300122":1},"content_text":"Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance notice (No. CXSL2501083) from the National Medical Products Administration (NMPA) for the clinical trial application of its Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine.\nIf no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with clinical trials according to the submitted protocol.\nThe vaccine adopts an attenuated live vaccine technology route, utilizing the Modified Vaccinia Ankara (MVA) strain for production. The MVA strain cannot effectively replicate in human cells, preventing systemic spread or secondary transmission, thereby ensuring high safety.\nThe acceptance of this clinical trial application marks a critical breakthrough in the company's emerging infectious disease vaccine portfolio, demonstrating its commitment to innovation and core technological advancement. This milestone not only strengthens the company's long-term growth prospects but also enhances China's independent innovation capabilities in major infectious disease prevention and control.\nSuccessful development of this project will further diversify the company's vaccine pipeline, optimize its product portfolio, and reinforce its market competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165688332","isCrawlerRequest":true}